173 related articles for article (PubMed ID: 16289851)
1. Making sense of antisense.
Vidal L; Blagden S; Attard G; de Bono J
Eur J Cancer; 2005 Dec; 41(18):2812-8. PubMed ID: 16289851
[TBL] [Abstract][Full Text] [Related]
2. Toxicology of antisense therapeutics.
Jason TL; Koropatnick J; Berg RW
Toxicol Appl Pharmacol; 2004 Nov; 201(1):66-83. PubMed ID: 15519609
[TBL] [Abstract][Full Text] [Related]
3. Antisense applications for biological control.
Pan WH; Clawson GA
J Cell Biochem; 2006 May; 98(1):14-35. PubMed ID: 16440307
[TBL] [Abstract][Full Text] [Related]
4. Antisense therapy in malignant diseases: status quo and quo vadis?
Tamm I
Clin Sci (Lond); 2006 Apr; 110(4):427-42. PubMed ID: 16526947
[TBL] [Abstract][Full Text] [Related]
5. Antisense approaches to cancer gene therapy.
Mercola D; Cohen JS
Cancer Gene Ther; 1995 Mar; 2(1):47-59. PubMed ID: 7621254
[TBL] [Abstract][Full Text] [Related]
6. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy developments for pancreatic cancer.
Bhattacharyya M; Lemoine NR
Best Pract Res Clin Gastroenterol; 2006 Apr; 20(2):285-98. PubMed ID: 16549328
[TBL] [Abstract][Full Text] [Related]
8. Antisense therapy for cancer.
Gleave ME; Monia BP
Nat Rev Cancer; 2005 Jun; 5(6):468-79. PubMed ID: 15905854
[TBL] [Abstract][Full Text] [Related]
9. Antisense molecules for targeted cancer therapy.
Wacheck V; Zangemeister-Wittke U
Crit Rev Oncol Hematol; 2006 Jul; 59(1):65-73. PubMed ID: 16750913
[TBL] [Abstract][Full Text] [Related]
10. [Applications of antisense oligonucleotides in oncology].
Pierga JY; Cammilleri S; Benyahia B; Magdelénat H
Bull Cancer; 1994 Dec; 81(12):1023-42. PubMed ID: 7742591
[TBL] [Abstract][Full Text] [Related]
11. Nucleic acid therapeutics for hematologic malignancies--theoretical considerations.
Opalinska JB; Kalota A; Chattopadhyaya J; Damha M; Gewirtz AM
Ann N Y Acad Sci; 2006 Oct; 1082():124-36. PubMed ID: 17145934
[TBL] [Abstract][Full Text] [Related]
12. The role of antisense oligonucleotides in the treatment of bladder cancer.
Duggan BJ; Gray S; Johnston SR; Williamson K; Miyaki H; Gleave M
Urol Res; 2002 Jul; 30(3):137-47. PubMed ID: 12111175
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Bcl-2 family in cancer therapy.
Papadopoulos K
Semin Oncol; 2006 Aug; 33(4):449-56. PubMed ID: 16890799
[TBL] [Abstract][Full Text] [Related]
14. The future of antisense therapy: combination with anticancer treatments.
Biroccio A; Leonetti C; Zupi G
Oncogene; 2003 Sep; 22(42):6579-88. PubMed ID: 14528283
[TBL] [Abstract][Full Text] [Related]
15. A novel integrated strategy (full length gene targeting) for mRNA accessible site tagging combined with microarray hybridization/RNase H cleavage to screen effective antisense oligonucleotides.
Sun Y; Duan M; Lin R; Wang D; Li C; Bo X; Wang S
Mol Vis; 2006 Nov; 12():1364-71. PubMed ID: 17149362
[TBL] [Abstract][Full Text] [Related]
16. Bcl-2 family members as molecular targets in cancer therapy.
Marzo I; Naval J
Biochem Pharmacol; 2008 Oct; 76(8):939-46. PubMed ID: 18638457
[TBL] [Abstract][Full Text] [Related]
17. Antisense treatments for biothreat agents.
Warfield KL; Panchal RG; Aman MJ; Bavari S
Curr Opin Mol Ther; 2006 Apr; 8(2):93-103. PubMed ID: 16610760
[TBL] [Abstract][Full Text] [Related]
18. siRNA-based approaches in cancer therapy.
Devi GR
Cancer Gene Ther; 2006 Sep; 13(9):819-29. PubMed ID: 16424918
[TBL] [Abstract][Full Text] [Related]
19. [Antisense oligonucleotides are clinically tested. They inhibit the expression of disease-related genes].
Sommer W; Heilig M
Lakartidningen; 1999 Jan; 96(4):348-54. PubMed ID: 10024826
[TBL] [Abstract][Full Text] [Related]
20. Antisense oligonucleotides and prevention of tumor growth: a different approach and proposal for a new method.
Yildiz D; Oztas H; Hilal Ates B
Med Hypotheses; 2005; 64(2):328-32. PubMed ID: 15607566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
